Medication and suicide risk in schizophrenia: A nested case-control study

Schizophrenia Research

Volumn 150, Issue 2-3, 2013, Pages 416-420

  Reutfors, Johan ^a   Bahmanyar, Shahram ^a,b   Jönsson, Erik G ^a   Brandt, Lena ^a   Bodén, Robert ^a,c   Ekbom, Anders ^a   Ösby, Urban ^a,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UPPSALA UNIVERSITY   (Sweden)

^d Tiohundra AB ^*  (Sweden)

Author keywords

Antidepressant drugs; Antipsychotic drugs; Case control study; Lithium; Schizophrenia; Suicide

Indexed keywords

ANTIDEPRESSANT AGENT; CLOZAPINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG RESPONSE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUICIDE;

ANTIDEPRESSANT DRUGS; ANTIPSYCHOTIC DRUGS; CASE-CONTROL STUDY; LITHIUM; SCHIZOPHRENIA; SUICIDE;

ADOLESCENT; ADULT; AGE FACTORS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LITHIUM CHLORIDE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ODDS RATIO; RISK; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SELF-INJURIOUS BEHAVIOR; SEX FACTORS; SUICIDE; YOUNG ADULT;

EID: 84886296782     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.09.001     Document Type: Article

References (38)

1. Aguilar E.J., Siris S.G. Do antipsychotic drugs influence suicidal behavior in schizophrenia?. Psychopharmacol. Bull. 2007, 40(3):128-142.
2. Altamura A.C., Bassetti R., Bignotti S., Pioli R., Mundo E. Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr. Res. 2003, 60(1):47-55.
3. Barak Y., Mirecki I., Knobler H.Y., Natan Z., Aizenberg D. Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period. Psychopharmacology (Berl) 2004, 175(2):215-219.
4. Cipriani A., Pretty H., Hawton K., Geddes J.R. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am. J. Psychiatry 2005, 162(10):1805-1819.
5. Ernst C.L., Goldberg J.F. Antisuicide properties of psychotropic drugs: a critical review. Harv. Rev. Psychiatry. 2004, 12(1):14-41.
6. Guzzetta F., Tondo L., Centorrino F., Baldessarini R.J. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J. Clin. Psychiatry 2007, 68(3):380-383.
7. Hawton K., Sutton L., Haw C., Sinclair J., Deeks J.J. Schizophrenia and suicide: systematic review of risk factors. Br. J. Psychiatry 2005, 187:9-20.
8. Khan A., Khan S.R., Leventhal R.M., Brown W.A. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database. Am. J. Psychiatry 2001, 158(9):1449-1454.
9. Leucht S., Kissling W., McGrath J. Lithium for schizophrenia. Cochrane Database Syst. Rev. 2007, (3). (Art. No.: CD003834). 10.1002/14651858.CD003834.pub2.
10. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373(9657):31-41.
11. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353(12):1209-1223.
12. Ludvigsson J.F., Andersson E., Ekbom A., Feychting M., Kim J.L., Reuterwall C., et al. External review and validation of the Swedish national inpatient register. BMC Publ. Health 2011, 11:450.
13. Mantovani C., Labate C.M., Sponholz A., de Azevedo Marques J.M., Guapo V.G., de Simone Brito dos Santos M.E., et al. Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated-blind trial of 4 intramuscular interventions. J. Clin. Psychopharmacol. 2013, 33(3):306-312.
14. Meltzer H. Clozapine and suicide. Am. J. Psychiatry 2002, 159(2):323-324.
15. Meltzer H.Y., Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am. J. Psychiatry 1995, 152(2):183-190.
16. Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 2003, 60(1):82-91.
17. Miller D.D. Atypical antipsychotics: sleep, sedation, and efficacy. Prim. Care Companion J. Clin. Psychiatry 2004, 6(Suppl. 2):3-7.
18. Montout C., Casadebaig F., Lagnaoui R., Verdoux H., Philippe A., Begaud B., et al. Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophr. Res. 2002, 57(2-3):147-156.
19. NICE The NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care 2009, National Institute for Health and Clinical Excellence, London, (www.nice.org.uk/cg82. Accessed on June 16, 2013).
20. Nordentoft M., Mortensen P.B., Pedersen C.B. Absolute risk of suicide after first hospital contact in mental disorder. Arch. Gen. Psychiatry 2011, 68(10):1058-1064.
21. Palmer B.A., Pankratz V.S., Bostwick J.M. The lifetime risk of suicide in schizophrenia: a reexamination. Arch. Gen. Psychiatry 2005, 62(3):247-253.
22. Pearce N. What does the odds ratio estimate in a case-control study?. Int. J. Epidemiol. 1993, 22(6):1189-1192.
23. Pompili M., Lester D., Grispini A., Innamorati M., Calandro F., Iliceto P., et al. Completed suicide in schizophrenia: evidence from a case-control study. Psychiatry Res. 2009, 167(3):251-257.
24. Pompili M., Serafini G., Innamorati M., Lester D., Shrivastava A., Girardi P., et al. Suicide risk in first episode psychosis: a selective review of the current literature. Schizophr. Res. 2011, 129(1):1-11.
25. Qin P., Nordentoft M. Suicide risk in relation to psychiatric hospitalization: evidence based on longitudinal registers. Arch. Gen. Psychiatry 2005, 62(4):427-432.
26. Reid W.H., Mason M., Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr. Serv. 1998, 49(8):1029-1033.
27. Reutfors J., Brandt L., Jönsson E.G., Ekbom A., Sparén P., Ösby U. Risk factors for suicide in schizophrenia: findings from a Swedish population-based case-control study. Schizophr. Res. 2009, 108(1-3):231-237.
28. Reutfors J., Brandt L., Ekbom A., Isacsson G., Sparén P., Ösby U. Suicide and hospitalization for mental disorders in Sweden: a population-based case-control study. J. Psychiatr. Res. 2010, 44(12):741-747.
29. Reutfors J., Bahmanyar S., Jönsson E.G., Ekbom A., Nordström P., Brandt L., et al. Diagnostic profile and suicide risk in schizophrenia spectrum disorder. Schizophr. Res. 2010, 123(2-3):251-256.
30. Roy A. Suicide in chronic schizophrenia. Br. J. Psychiatry 1982, 141:171-177.
31. Sernyak M.J., Desai R., Stolar M., Rosenheck R. Impact of clozapine on completed suicide. Am. J. Psychiatry 2001, 158(6):931-937.
32. Storosum J.G., van Zwieten B.J., Wohlfarth T., de Haan L., Khan A., van den Brink W. Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia. Arch. Gen. Psychiatry 2003, 60(4):365-368.
33. Strom B.L., Eng S.M., Faich G., Reynolds R.F., D'Agostino R.B., Ruskin J., et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am. J. Psychiatry 2011, 168(2):193-201.
34. Tiihonen J., Wahlbeck K., Lönnqvist J., Klaukka T., Ioannidis J.P., Volavka J., et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006, 333(7561):224.
35. Tiihonen J., Lönnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A., et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374(9690):620-627.
36. Tiihonen J., Suokas J.T., Suvisaari J.M., Haukka J., Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch. Gen. Psychiatry 2012, 69(5):476-483.
37. Vares M., Saetre P., Stralin P., Levander S., Lindström E., Jönsson E.G. Concomitant medication of psychoses in a lifetime perspective. Hum. Psychopharmacol. 2011, 26(4-5):322-331.
38. Walker A.M., Lanza L.L., Arellano F., Rothman K.J. Mortality in current and former users of clozapine. Epidemiology 1997, 8(6):671-677.